Levels of soluble adhesion molecules in @entity1 with various clinical presentations of XXXX .

@entity1 @entity32 @entity583 @entity731 @entity4105 @entity951 @entity2071 @entity8729 @entity4725 @entity453 @entity13551
BACKGROUND: Adhesion molecules play an important role in the development and progression of @entity453 . The aim of this study was to compare concentrations of soluble forms of adhesion molecules in @entity1 with different clinical presentations of @entity453 ( @entity453 ). METHODS: One hundred and twenty-eight @entity1 with @entity453 were divided into three groups; the first group was @entity583 group (AMI group, n = 45), the second group was unstable @entity951 group (UAP group, n = 48), the third group was stable @entity951 group ( @entity13551 group, n = 35). We compared them with @entity1 with normal coronary arteries (control group, n = 31). The serum levels of vascular cell adhesion molecule ( @entity4725 ), @entity2071 ( @entity2071 ), @entity4105 and @entity8729 were measured in all subjects. RESULTS: The serum level of @entity4725 in the AMI group was significantly higher than in the UAP, @entity13551 and control groups (P < 0.01). The level in the UAP group was significantly higher than the @entity13551 group and control group (P < 0.01) and the level in the @entity13551 group was significantly higher than in the control group (P < 0.01). The serum @entity2071 level was significantly elevated in the AMI, UAP and @entity13551 groups as compared to the control group (P < 0.01). The levels of serum @entity4105 and @entity8729 in the AMI and UAP groups were significantly higher than in the @entity13551 and control groups (P < 0.01). CONCLUSIONS: Increased levels of @entity4725 and @entity2071 , @entity4105 and @entity8729 , as markers of @entity32 , showed the importance of inflammatory processes in the development of @entity731 and clinical expression of @entity453 . Soluble @entity2071 , @entity4725 , @entity4105 and @entity8729 concentrations are useful indicators of the presence of @entity731 and the severity of @entity453 clinical presentation.
